ASXL1 and chronic myelomonocytic leukemia: In MDS and younger patients with CMML (age <65 years), the presence of clonal TET2 mutations, in the absence of clonal ASXL1 mutations, has been associated with a favorable response to hypomethylating agents (5–azacitidine and decitabine).38, 39 Treatment data on this study cohort was incomplete.37